ClinicalTrials.gg
Active, not recruitingNCT07232004Updated Oct 15, 2026

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

A Phase 1 interventional study of ABBV-547 and ABBV-547 Placebo in Healthy Volunteer and Psoriasis, sponsored by AbbVie. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 79 studies in Psoriasis by AbbVie — 2 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · AbbVie.

Planned enrollment
28th of 48
142 · median 166
Started
2025
with 1 other
Phase 1
6 of 79
none open now
Registered
78th of 79
by date

Among the 79 studies in Psoriasis by AbbVie, this one is the 28th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 78th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 79 studies in Psoriasis by AbbVie are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Psoriasis by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan.

There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan.

Participants will be administered one dose or multiple doses of ABBV-547 or placebo.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Healthy Volunteer
  • Psoriasis

Browse trials for

Keywords

  • Healthy Volunteer
  • ABBV-547
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG).
  • Part 1: is >= 18.0 to \<= 29.9 kg/m\^2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Part 2: must have discontinued use of phototherapy (e.g., UVA or UVB) at least 2 weeks prior to the baseline visit (Day 1) and PUVA phototherapy at least 4 weeks prior to the baseline visit (Day 1).

Exclusion criteria

Exclusion Criteria:

  • History of any sensitivity or allergy to any medication or food.
  • Part 2: uses any herbal supplements within the 2-week period prior to study treatment administration.
  • Part 2: received any biologics including agents within 2.5 half-lives prior to Baseline.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Group 1: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 2: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 3: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 4: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 5: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 6: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 7: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 8: ABBV-547 & Placebo

    Japanese participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 9: ABBV-547 & Placebo

    Han Chinese participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 10: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

  • Experimental
    Group 11: ABBV-547 & Placebo

    Participants will receive either ABBV-547 or placebo.

    Drug: ABBV-547 · Drug: ABBV-547 Placebo

Interventions

  • DrugABBV-547

    Parental Administration

  • DrugABBV-547 Placebo

    Parental Administration

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately Day 365

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for May 2028, 30 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 30 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Aug 2027 → May 2028 and completion Aug 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 17, 2025
StartActual
Nov 24, 2025
Primary completionEst.
May 2028was Aug 2027
CompletionEst.
May 2028was Aug 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 5 sites removed
Show 2 added (2 United States)
  • CenExel Act- Anaheim Clinical Trials /ID# 279612 · Anaheim, United States
  • The Skin Center Dermatology Group. /ID# 279983 · New City, United States
Show 5 removed
  • CenExel ACT- Anaheim Clinical Trials /ID# 279612 · Anaheim, United States
  • Skin Care Research Boca Raton /ID# 279988 · Boca Raton, United States
  • Trueblue Clinical Research - Tampa /ID# 281757 · Tampa, United States
  • University Dermatology & Vein Clinic - Darien /ID# 279986 · Darien, United States
  • The Skin Center Dermatology Group /ID# 279983 · New City, United States
Oct 15, 2026
Primary completion
Aug 2027→May 2028
Oct 15, 2026
Study completion
Aug 2027→May 2028
Oct 15, 2026
Enrollment
121→142
Oct 15, 2026
Eligibility
Maximum age 55 Years→70 Years
Oct 15, 2026
Interventions
Arms added: Group 11: ABBV-547 & Placebo
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    2 sites added, 5 sites removed
    Show 2 added (2 United States)
    • CenExel Act- Anaheim Clinical Trials /ID# 279612 · Anaheim, United States
    • The Skin Center Dermatology Group. /ID# 279983 · New City, United States
    Show 5 removed
    • CenExel ACT- Anaheim Clinical Trials /ID# 279612 · Anaheim, United States
    • Skin Care Research Boca Raton /ID# 279988 · Boca Raton, United States
    • Trueblue Clinical Research - Tampa /ID# 281757 · Tampa, United States
    • University Dermatology & Vein Clinic - Darien /ID# 279986 · Darien, United States
    • The Skin Center Dermatology Group /ID# 279983 · New City, United States
    Primary completion Aug 2027→May 2028
    Study completion Aug 2027→May 2028
    Enrollment 121→142
    Eligibility Maximum age 55 Years→70 Years
    Interventions Arms added: Group 11: ABBV-547 & Placebo
    + 5 other changes: index terms, identifiers, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232004
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 24, 2025
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion